BeOne Medicines has announced that the USFDA has granted accelerated approval to BEQALZI, a next-generation BCL2 inhibitor, for adult patients with relapsed or refractory (R/R) mantle cell lymphoma (MCL).
The approval marks a significant step in a difficult-to-treat cancer setting where options narrow sharply after BTK inhibitor failure.
BEQALZI is designed to deliver enhanced BCL2 inhibition with greater potency and selectivity, alongside a pharmacologic profile intended to improve efficacy, tolerability, and convenience compared with other drugs in its class.
Michael Wang, Global Principal Investigator, the Puddin Clarke Endowed Professor, Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, said: "The data supporting the approval of sonrotoclax in the U.S. confirm its role as a foundational therapy for mantle cell lymphoma in the post-BTK inhibitor setting."
The FDA’s accelerated approval is backed by data from the Phase 1/2 study BGB-11417-201.
Amit Agarwal, Chief Medical Officer, Hematology, BeOne Medicines, said: "BeOne is leading the advancement and enhancement of BCL2 inhibition to revolutionize how we treat patients living with B-cell malignancies.
"Today’s approval of BEQALZI represents critical progress for patients with mantle cell lymphoma and reinforces our strategy of building foundational medicines designed to raise the standard of care in B-cell malignancies.”
